Niagen Bioscience (NAGE) Receivables (2011 - 2026)

Niagen Bioscience (NAGE) has 16 years of Receivables data on file, last reported at $16.5 million in Q1 2026.

• On a quarterly basis, Receivables rose 226.13% year-over-year to $16.5 million in Q1 2026; TTM through Mar 2026 was $16.5 million, a 226.13% increase from a year earlier, with the FY2025 full-year figure at $10.5 million, up 16.03% from the prior year.
• Receivables for Q1 2026 stood at $16.5 million, up from $11.0 million in the prior quarter.
• Over the last five years, Receivables for NAGE reached as high as $16.5 million in Q1 2026 and fell as low as $132000.0 in Q2 2023.
• Historically, Receivables has averaged $7.9 million across 5 years, with a median of $7.3 million in 2025.
• Across the five-year window, Receivables sank 97.61% in 2023 and jumped 6751.52% in 2024, its largest moves.
• Year by year, Receivables stood at $12.3 million in 2022, then plunged by 79.99% to $2.5 million in 2023, then jumped by 190.62% to $7.1 million in 2024, then soared by 54.41% to $11.0 million in 2025, then soared by 50.07% to $16.5 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $16.5 million in Q1 2026, $11.0 million in Q4 2025, and $7.3 million in Q3 2025.